Hyundai Bioscience현대바이오
048410 · KOSDAQ · ₩048410 · 현대바이오
₩5,870▲ ₩50 (0.86%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | −6.6% | 6.9% | 78.8% | 53.2% | 34.2% | 38.1% |
| Operating margin | −580.0% | −516.3% | 5.3% | −103.2% | −335.7% | −105.7% |
| Net margin | −861.5% | −629.1% | −46.0% | −152.9% | −201.3% | −217.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −5.6% | −76.6% | +58.7% | +20.8% | −15.0% | — |
| Operating income growth | −6.1% | −2,396.0% | +108.1% | +62.9% | −169.7% | — |
| Net income growth | −29.3% | −219.3% | +52.2% | +8.3% | +21.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −26.7% | −29.5% | −16.4% | −28.0% | −26.4% | −32.6% |
| Return on assets | −21.8% | −22.3% | −11.5% | −24.1% | −21.4% | −24.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 27.1% | 18.1% | 71.7% | 16.6% | 15.6% | 30.8% |
| Net debt to equity | −19.9% | −20.6% | 56.2% | −14.2% | 5.6% | 9.4% |
| Current ratio | 236.4% | 225.3% | 24.8% | 218.3% | 286.4% | 209.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Hyundai Bioscience / 현대바이오 / 048410 / KRX:048410
Source: KRX statistical information